$52.13
0.0850.16%
Travere Therapeutics Inc
TVTXNASDAQ
Travere Therapeutics (TVTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Travere Therapeutics (TVTX) last issued guidance on January 9, 2023 for fiscal year 2022. The company guided revenue in the range of $212M - $212M for the period.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.23 | $-0.10 | $0.24 | $-0.17 |
| Actual | $-0.10 | $0.05 | $0.37 | $0.59 |
| Surprise | -143.5% | +150.0% | +54.2% | +447.1% |
| Revenue | ||||
| Estimate | $159.3M | $135.3M | $145.6M | $105.0M |
| Actual | $169.6M | $127.2M | $129.7M | $164.9M |
| Surprise | +6.44% | -6.01% | -10.9% | +57.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.40 | $0.95 | $0.56 | $0.80 |
| Revenue | ||||
| Consensus | $194.9M | $231.5M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-0.10 | $0.23 | -143.5 % |
| Q1 | May 4, 2026 | $0.05 | $-0.10 | 150.0 % |
| Q4 | Feb 19, 2026 | $0.37 | $0.24 | 54.2 % |
| Q3 | Oct 30, 2025 | $0.59 | $-0.17 | 447.1 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $169.58M | $159.32M | 6.44 % |
| Q1 | May 4, 2026 | $127.20M | $135.34M | -6.01 % |
| Q4 | Feb 19, 2026 | $129.69M | $145.59M | -10.9 % |
| Q3 | Oct 30, 2025 | $164.86M | $105.01M | 57.0 % |
